Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors.

Kasai Y, Mahuron K, Hirose K, Corvera CU, Kim GE, Hope TA, Shih BE, Warren RS, Bergsland EK, Nakakura EK.

J Surg Oncol. 2019 Oct 15. doi: 10.1002/jso.25727. [Epub ahead of print]

PMID:
31613999
2.

High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.

Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS.

PLoS One. 2019 Jul 10;14(7):e0219469. doi: 10.1371/journal.pone.0219469. eCollection 2019.

3.

Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors.

Chan H, Moseley C, Zhang L, Bergsland EK, Pampaloni MH, Van Loon K, Hope TA.

Pancreas. 2019 Aug;48(7):948-952. doi: 10.1097/MPA.0000000000001356.

PMID:
31268975
4.

Periprocedural Management of Patients Undergoing Liver Resection or Embolotherapy for Neuroendocrine Tumor Metastases.

Kwon DH, Paciorek A, Mulvey CK, Chan H, Fidelman N, Meng L, Nakakura EK, Zhang L, Bergsland EK, Van Loon K.

Pancreas. 2019 Apr;48(4):496-503. doi: 10.1097/MPA.0000000000001271.

PMID:
30946246
5.

Mitogen Inducible Gene-6 Is a Prognostic Marker for Patients with Colorectal Liver Metastases.

Donner DB, Ruan DT, Toriguchi K, Bergsland EK, Nakakura EK, Lin MH, Antonia RJ, Warren RS.

Transl Oncol. 2019 Mar;12(3):550-560. doi: 10.1016/j.tranon.2018.12.007. Epub 2019 Jan 9.

6.

Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.

Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH.

Oncologist. 2019 Aug;24(8):1066-1075. doi: 10.1634/theoncologist.2018-0520. Epub 2019 Jan 4.

PMID:
30610008
7.

Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.

Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK.

Oncologist. 2019 Aug;24(8):1056-1065. doi: 10.1634/theoncologist.2018-0519. Epub 2019 Jan 3.

PMID:
30606883
8.

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors.

Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK.

Mol Cancer Ther. 2018 Dec;17(12):2702-2709. doi: 10.1158/1535-7163.MCT-17-1204. Epub 2018 Sep 25.

PMID:
30254185
9.

Progress in the Evaluation and Treatment of Small Bowel Neuroendocrine Tumors.

Mulvey CK, Bergsland EK.

J Oncol Pract. 2018 Aug;14(8):487-489. doi: 10.1200/JOP.18.00440. No abstract available.

PMID:
30096272
10.

Vitamin D Levels in Patients with Colorectal Cancer Before and After Treatment Initiation.

Savoie MB, Paciorek A, Zhang L, Van Blarigan EL, Sommovilla N, Abrams D, Atreya CE, Bergsland EK, Chern H, Kelley RK, Ko A, Laffan A, Sarin A, Varma MG, Venook AP, Van Loon K.

J Gastrointest Cancer. 2018 Jul 30. doi: 10.1007/s12029-018-0147-7. [Epub ahead of print]

PMID:
30058032
11.

Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.

Hope TA, Bergsland EK, Bozkurt MF, Graham M, Heaney AP, Herrmann K, Howe JR, Kulke MH, Kunz PL, Mailman J, May L, Metz DC, Millo C, O'Dorisio S, Reidy-Lagunes DL, Soulen MC, Strosberg JR.

J Nucl Med. 2018 Jan;59(1):66-74. doi: 10.2967/jnumed.117.202275. Epub 2017 Oct 12. No abstract available.

12.

The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF.

Pancreas. 2017 Jul;46(6):715-731. doi: 10.1097/MPA.0000000000000846. Review.

13.

The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors.

Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK.

Pancreas. 2017 Jul;46(6):707-714. doi: 10.1097/MPA.0000000000000850. Review.

14.

A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases.

Wang VE, Young L, Ali S, Miller VA, Urisman A, Wolfe J, Bivona TG, Damato B, Fogh S, Bergsland EK.

Oncologist. 2017 Jul;22(7):768-773. doi: 10.1634/theoncologist.2017-0054. Epub 2017 May 15.

15.

Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.

Hege KM, Bergsland EK, Fisher GA, Nemunaitis JJ, Warren RS, McArthur JG, Lin AA, Schlom J, June CH, Sherwin SA.

J Immunother Cancer. 2017 Mar 21;5:22. doi: 10.1186/s40425-017-0222-9. eCollection 2017.

16.

Lower gastrointestinal neuroendocrine neoplasms associated with hereditary cancer syndromes: a case series.

Kidambi TD, Pedley C, Blanco A, Bergsland EK, Terdiman JP.

Fam Cancer. 2017 Oct;16(4):537-543. doi: 10.1007/s10689-017-9979-8.

PMID:
28283864
17.

Complicated Case Presentation: Management of Pancreatic Neuroendocrine Tumors in Multiple Endocrine Neoplasia Type 1.

Mulvey CK, Van Loon K, Bergsland EK, Masharani U, Nakakura EK.

Pancreas. 2017 Mar;46(3):416-426. doi: 10.1097/MPA.0000000000000770. Review.

PMID:
28187108
18.

Radioembolization with 90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: final report of a prospective pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Pampaloni M, Taylor AG, Kohi MP, Kolli KP, Atreya CE, Bergsland EK, Kelley RK, Ko AH, Korn WM, Van Loon K, McWhirter RM, Luan J, Johanson C, Venook AP.

J Gastrointest Oncol. 2016 Dec;7(6):860-874. doi: 10.21037/jgo.2016.08.04.

19.

Oxaliplatin-Fluoropyrimidine Chemotherapy Plus Bevacizumab in Advanced Neuroendocrine Tumors: An Analysis of 2 Phase II Trials.

Kunz PL, Balise RR, Fehrenbacher L, Pan M, Venook AP, Fisher GA, Tempero MA, Ko AH, Korn WM, Hwang J, Bergsland EK.

Pancreas. 2016 Nov;45(10):1394-1400.

PMID:
27171514
20.

A phase II study of axitinib in advanced neuroendocrine tumors.

Strosberg JR, Cives M, Hwang J, Weber T, Nickerson M, Atreya CE, Venook A, Kelley RK, Valone T, Morse B, Coppola D, Bergsland EK.

Endocr Relat Cancer. 2016 May;23(5):411-8. doi: 10.1530/ERC-16-0008. Epub 2016 Apr 14.

21.

Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors.

Mulvey CK, Bergsland EK.

Hematol Oncol Clin North Am. 2016 Feb;30(1):63-82. doi: 10.1016/j.hoc.2015.09.002. Review.

PMID:
26614369
22.

Correcting for respiratory motion in liver PET/MRI: preliminary evaluation of the utility of bellows and navigated hepatobiliary phase imaging.

Hope TA, Verdin EF, Bergsland EK, Ohliger MA, Corvera CU, Nakakura EK.

EJNMMI Phys. 2015 Dec;2(1):21. doi: 10.1186/s40658-015-0125-0. Epub 2015 Sep 18.

23.

Transcatheter pulmonic valve replacement in carcinoid heart disease.

Heidecker B, Moore P, Bergsland EK, Merrick SH, Rao RK.

Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):1046. doi: 10.1093/ehjci/jev121. Epub 2015 May 23. No abstract available.

PMID:
26003151
24.

Combined mammalian target of rapamycin and vascular endothelial growth factor pathway inhibition in pancreatic neuroendocrine tumors: more than the sum of its parts?

Bergsland EK.

J Clin Oncol. 2015 May 10;33(14):1523-6. doi: 10.1200/JCO.2014.58.6974. Epub 2015 Feb 2. No abstract available.

PMID:
25646187
25.

Is more not better?: combination therapies in colorectal cancer treatment.

Bergsland EK.

Hematol Oncol Clin North Am. 2015 Feb;29(1):85-116. doi: 10.1016/j.hoc.2014.09.002. Review.

PMID:
25475574
26.

Bone metastases and skeletal-related events from neuroendocrine tumors.

Van Loon K, Zhang L, Keiser J, Carrasco C, Glass K, Ramirez MT, Bobiak S, Nakakura EK, Venook AP, Shah MH, Bergsland EK.

Endocr Connect. 2015 Mar;4(1):9-17. doi: 10.1530/EC-14-0119. Epub 2014 Nov 27.

27.

Neuroendocrine tumors of unknown primary: is the primary site really not known?

Bergsland EK, Nakakura EK.

JAMA Surg. 2014 Sep;149(9):889-90. doi: 10.1001/jamasurg.2014.216. No abstract available.

PMID:
25029597
28.

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial.

Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J, Maughan T, Castillo MG, Iveson T, Yin D, Green S, Bergsland EK.

Cancer Chemother Pharmacol. 2014 Apr;73(4):695-702. doi: 10.1007/s00280-014-2391-2. Epub 2014 Feb 1.

PMID:
24488322
29.

90Y glass microspheres for the treatment of unresectable metastatic liver disease from chemotherapy-refractory gastrointestinal cancers: a pilot study.

Fidelman N, Kerlan RK Jr, Hawkins RA, Taylor AG, Kohi MP, Kolli KP, Bergsland EK, Kelley RK, Ko AH, Korn WM, McWhirter RM, Luan J, Venook AP.

J Gastrointest Cancer. 2014 Jun;45(2):168-80. doi: 10.1007/s12029-013-9566-7.

PMID:
24448917
30.

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK.

Br J Cancer. 2013 Oct 1;109(7):1725-34. doi: 10.1038/bjc.2013.553. Epub 2013 Sep 10.

31.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors.

Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS.

Oncogene. 2014 Mar 20;33(12):1590-600. doi: 10.1038/onc.2013.92. Epub 2013 Apr 1.

32.

Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.

Kelley RK, Nimeiri HS, Munster PN, Vergo MT, Huang Y, Li CM, Hwang J, Mulcahy MF, Yeh BM, Kuhn P, Luttgen MS, Grabowsky JA, Stucky-Marshall L, Korn WM, Ko AH, Bergsland EK, Benson AB 3rd, Venook AP.

Ann Oncol. 2013 Jul;24(7):1900-7. doi: 10.1093/annonc/mdt109. Epub 2013 Mar 21.

33.

The evolving landscape of neuroendocrine tumors.

Bergsland EK.

Semin Oncol. 2013 Feb;40(1):4-22. doi: 10.1053/j.seminoncol.2012.11.013. Review. Erratum in: Semin Oncol. 2013 Apr;40(2):239.

PMID:
23391109
34.

Introduction: recent advances in the genetics, diagnosis, and treatment of neuroendocrine tumors.

Bergsland EK.

Semin Oncol. 2013 Feb;40(1):1-3. doi: 10.1053/j.seminoncol.2012.12.001. No abstract available.

PMID:
23391108
35.

Lymph node sampling rates and predictors of nodal metastasis in pancreatic neuroendocrine tumor resections: the UCSF experience with 149 patients.

Parekh JR, Wang SC, Bergsland EK, Venook AP, Warren RS, Kim GE, Nakakura EK.

Pancreas. 2012 Aug;41(6):840-4. doi: 10.1097/MPA.0b013e31823cdaa0.

PMID:
22781907
36.

Systemic therapy for advanced carcinoid tumors: where do we go from here?

Paulson AS, Bergsland EK.

J Natl Compr Canc Netw. 2012 Jun 1;10(6):785-93. Review.

PMID:
22679120
37.

Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer.

Atreya CE, Ducker GS, Feldman ME, Bergsland EK, Warren RS, Shokat KM.

Invest New Drugs. 2012 Dec;30(6):2219-25. doi: 10.1007/s10637-012-9793-y. Epub 2012 Jan 24.

PMID:
22270257
38.

Optimizing the administration of fixed-dose rate gemcitabine plus capecitabine using an alternating-week schedule: a dose finding and early efficacy study in advanced pancreatic and biliary carcinomas.

Ko AH, Espinoza AM, Jones KA, Venook AP, Bergsland EK, Kelley RK, Dito E, Ong A, Hanover CS, Coakley FV, Tempero MA.

Am J Clin Oncol. 2012 Oct;35(5):411-7.

PMID:
21552099
39.

Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial.

Garcia-Aguilar J, Smith DD, Avila K, Bergsland EK, Chu P, Krieg RM; Timing of Rectal Cancer Response to Chemoradiation Consortium.

Ann Surg. 2011 Jul;254(1):97-102. doi: 10.1097/SLA.0b013e3182196e1f.

40.

Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting.

Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, Ellis LM, Benedetti JK, Bergsland EK, Hobday TJ, Van Cutsem E, Pingpank J, Oberg K, Cohen SJ, Posner MC, Yao JC.

J Clin Oncol. 2011 Mar 1;29(7):934-43. doi: 10.1200/JCO.2010.33.2056. Epub 2011 Jan 24.

41.

Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site.

Wang YC, Iezza G, Zuraek MB, Jablons DM, Theodore PR, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

J Surg Res. 2010 Sep;163(1):47-51. doi: 10.1016/j.jss.2010.04.018. Epub 2010 May 6.

PMID:
20599218
42.

Identification of unknown primary tumors in patients with neuroendocrine liver metastases.

Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, Nakakura EK.

Arch Surg. 2010 Mar;145(3):276-80. doi: 10.1001/archsurg.2010.10.

PMID:
20231629
43.

A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer.

Ko AH, Venook AP, Bergsland EK, Kelley RK, Korn WM, Dito E, Schillinger B, Scott J, Hwang J, Tempero MA.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1051-7. doi: 10.1007/s00280-010-1257-5. Epub 2010 Feb 4.

PMID:
20130876
44.

The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine.

Wang YC, Zuraek MB, Kosaka Y, Ota Y, German MS, Deneris ES, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

Endocr Relat Cancer. 2010 Feb 18;17(1):283-91. doi: 10.1677/ERC-09-0243. Print 2010 Mar.

PMID:
20048018
45.

Glycemic control in patients with insulinoma treated with everolimus.

Kulke MH, Bergsland EK, Yao JC.

N Engl J Med. 2009 Jan 8;360(2):195-7. doi: 10.1056/NEJMc0806740. No abstract available.

PMID:
19129539
46.

Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors.

Wang YC, Gallego-Arteche E, Iezza G, Yuan X, Matli MR, Choo SP, Zuraek MB, Gogia R, Lynn FC, German MS, Bergsland EK, Donner DB, Warren RS, Nakakura EK.

Endocr Relat Cancer. 2009 Mar;16(1):267-79. doi: 10.1677/ERC-08-0127. Epub 2008 Nov 5.

PMID:
18987169
47.

Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy.

Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA.

Pancreas. 2008 Oct;37(3):269-74. doi: 10.1097/MPA.0b013e31816d8185.

PMID:
18815548
48.

A phase II study evaluating bevacizumab in combination with fixed-dose rate gemcitabine and low-dose cisplatin for metastatic pancreatic cancer: is an anti-VEGF strategy still applicable?

Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA.

Invest New Drugs. 2008 Oct;26(5):463-71. doi: 10.1007/s10637-008-9127-2. Epub 2008 Apr 1.

PMID:
18379729
49.

Excess toxicity associated with docetaxel and irinotecan in patients with metastatic, gemcitabine-refractory pancreatic cancer: results of a phase II study.

Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.

Cancer Invest. 2008 Feb;26(1):47-52. doi: 10.1080/07357900701681483.

PMID:
18181045
50.

Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.

Saltz LB, Rosen LS, Marshall JL, Belt RJ, Hurwitz HI, Eckhardt SG, Bergsland EK, Haller DG, Lockhart AC, Rocha Lima CM, Huang X, DePrimo SE, Chow-Maneval E, Chao RC, Lenz HJ.

J Clin Oncol. 2007 Oct 20;25(30):4793-9. Erratum in: J Clin Oncol. 2008 Jan 20;26(3):514.

PMID:
17947727

Supplemental Content

Loading ...
Support Center